General Information of Drug (ID: DM6Y1QF)

Drug Name
BMS-488516 Drug Info
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Investigative [1]
Cross-matching ID
PubChem CID
11527400
TTD Drug ID
DM6Y1QF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JTE-051 DM2LBHN Plaque psoriasis EA90.0 Phase 2 [2]
CPI-818 DMMBQ20 T-cell lymphoma 2A90 Phase 1 [3]
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [4]
PMID27774824-Compound-Figure3Example7 DMXDOGK N. A. N. A. Patented [4]
BMS-509744 DMGH1LX Inflammation 1A00-CA43.1 Investigative [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell-specific kinase (ITK) TT3C80U ITK_HUMAN Inhibitor [1]

References

1 Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.
2 Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490.
3 Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
4 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.